Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Significant Increase in Short Interest

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 384,100 shares, an increase of 221.7% from the December 15th total of 119,400 shares. Based on an average daily volume of 493,500 shares, the days-to-cover ratio is presently 0.8 days. Currently, 2.1% of the company’s shares are short sold.

Xilio Therapeutics Price Performance

Shares of XLO opened at $1.08 on Thursday. The firm has a fifty day moving average of $1.03 and a 200-day moving average of $0.94. Xilio Therapeutics has a 1 year low of $0.50 and a 1 year high of $1.93.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of XLO. Geode Capital Management LLC grew its holdings in shares of Xilio Therapeutics by 85.0% during the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after buying an additional 155,337 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Xilio Therapeutics by 18.3% in the 2nd quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock valued at $280,000 after purchasing an additional 45,554 shares during the period. Finally, XTX Topco Ltd bought a new position in Xilio Therapeutics during the second quarter valued at about $32,000. 54.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Raymond James lowered their price target on shares of Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a report on Friday, November 8th.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.